Latest Oncotype DX Stories
New findings validate clinical utility in Colorectal Cancer Staging MONTREAL, May 16, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the Previstage(TM) GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology((R)) (ASCO((R))) Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013. The results of the...
REDWOOD CITY, Calif., May 10, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that, effective May 8, 2013, Palmetto GBA, the designated national contractor for its Oncotype DX® breast cancer test, has expanded its coverage policy for all qualified Medicare patients to include patients with ductal carcinoma in situ (DCIS) following the recent publication of the breast cancer test's DCIS Score in the peer-reviewed, Journal of the National Cancer Institute....
Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting SAN DIEGO, May 8, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American...
REDWOOD CITY, Calif., May 7, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the 2013 Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 14 at 5:00 p.m. Pacific Time (PT). (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website...
Findings Demonstrate Utility of Oncotype DX® to Guide Radiation Treatment Decision for DCIS Patients and Support Expanded Access and Reimbursement REDWOOD CITY, Calif. and PHILADELPHIA, May 2, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and the ECOG-ACRIN Cancer Research Group announced today that the Journal of the National Cancer Institute (JNCI) published positive results from their clinical validation study of the Oncotype DX® DCIS Score in patients with ductal...
Product Revenue Increased 8% Compared to Prior Year REDWOOD CITY, Calif., May 2, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Total revenue for the first quarter of 2013 increased to $63.1 million, compared with $58.5 million in the first quarter of 2012. Product revenue was $62.7 million in the first...
Revenues Continue to Ramp in 2013 IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint test analyzes 70 key genes and accurately determines which patients are at low risk of breast cancer recurrence and can therefore safely choose not to undergo chemotherapy. Case volume grew by more than...
Complete Results from UCSF-Led Validation Study to be Presented Earlier that Day at the American Urological Association (AUA) Annual Meeting in San Diego REDWOOD CITY,Calif., May 1, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will host an investor webcast and conference call to discuss the positive development and clinical validation study results of its biopsy-based Oncotype DX prostate cancer test on Wednesday, May 8, 2013 at...
REDWOOD CITY, Calif., April 25, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Thursday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2013 financial results. The call and webcast will follow the release of the first quarter financial results after market close. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Conference Call Details To access the live conference...
Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access REDWOOD CITY, Calif., April 17, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test in stage II colon cancer patients. The findings provide further...
